EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Nanoparticle Albumin‐Bound Paclitaxel and Nivolumab for PD ‐1 Inhibitor‐Refractory Recurrent or Metastatic Head and Neck Squamous‐Cell Carcinoma

Douglas Adkins, Jessica C Ley iD, Christine Auberle, Brendan Knapp, Jesse Zaretsky, Jingxia Liu iD, Peter Oppelt

Cancer Medicine · 2026

DOI: 10.1002/cam4.71533 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2026. Verfasst von Douglas Adkins und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Nivolumab, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Gregory Stubblefield and Nancy Apel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Standard therapy for PD‐1 inhibitor‐refractory recurrent or metastatic head and neck squamous‐cell carcinoma (RM‐HNSCC) has limited activity. Drugs bound to albumin selectively target cancer cells with upregulated macropinocytosis, a process driven by constitutively hyper‐activated EGFR/RAS/PIK3CA signaling, which is common in HNSCC. Nanoparticle albumin‐bound ( nab )‐paclitaxel is active in PD‐1 inhibitor‐naïve RM‐HNSCC and alters immune cells to potentially prime tumor response and reverse resistance to PD‐1 inhibitors.

Methods

In a single‐arm phase 2 trial, patients with PD‐1 inhibitor‐refractory RM‐HNSCC received nab‐ paclitaxel and nivolumab given in 28‐day cycles. The primary endpoint was objective response rate (ORR), using RECIST1.1. Key secondary endpoints were duration of response (DoR), progression‐free survival (PFS), and overall survival (OS). At least one tumor response assessment was required to be evaluable for ORR and PFS. A Simon optimal two‐stage design tested the primary hypothesis (ORR: H 1 ≥ 50 vs. H 0 ≤ 30%, type I error 0.05; power 0.80). H 0 was rejected if ≥ 19 responses were observed in 46 patients. This sample size had a power of 80% to detect the difference in the key secondary hypothesis (median PFS: H 1 6.0 vs. H 0 3.6 months, two‐sided, one‐sample log rank test; type I error 0.05).

Results

From 9/28/2021–1/4/2024, 46 patients enrolled into the trial. One patient was not evaluable for ORR and PFS. Tumor response occurred in 21 of 45 evaluable patients (ORR 46.7%, 95% CI: 33.8–59.9; vs. H 0 , p = 0.0073) and included confirmed response in 20 and unconfirmed response in 1. The best tumor response was complete (4), partial (17), stable (18), and progression (6). The median DoR was 6.1 months (95% CI: 2.8–9.4). With a median follow‐up of 14.1 months (IQR: 7.6–20.1), the median PFS was 5.5 months (95% CI: 3.9–7.8) and the median OS was 13.9 months (95% CI: 9.0–18.9). Treatment‐related deaths did not occur.

Conclusion

Among patients with PD‐1 inhibitor‐refractory RM‐HNSCC, nab ‐paclitaxel and nivolumab resulted in an ORR and median PFS that were better than historically reported with standard therapy. Trial Registration Trial registered on www.clinicaltrials.gov, National Clinical Trial (NCT) 04831320

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsAlbumin-Bound PaclitaxelPaclitaxelHumansMaleFemaleMiddle AgedAgedAlbuminsAdultProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmNanoparticles

Stichwörter der Autor:innen

head and neck cancernab‐paclitaxelnivolumabrecurrent and metastatic disease

Substanzen

NivolumabAlbuminsImmune Checkpoint InhibitorsAlbumin-Bound PaclitaxelPaclitaxelProgrammed Cell Death 1 Receptor130-nm albumin-bound paclitaxel

Autor:innen und Institutionen

  • Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri, USA.

ORCID-Profile: Jessica C Ley, Jingxia Liu

Förderung

  • Bristol-Myers Squibb
  • Gregory Stubblefield and Nancy Apel

Zitieren

APA

Adkins, D., Ley, J. C., Auberle, C., Knapp, B., Zaretsky, J., Liu, J., & Oppelt, P. (2026). Nanoparticle Albumin‐Bound Paclitaxel and Nivolumab for PD ‐1 Inhibitor‐Refractory Recurrent or Metastatic Head and Neck Squamous‐Cell Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71533

Vancouver

Adkins D, Ley JC, Auberle C, Knapp B, Zaretsky J, Liu J, et al. Nanoparticle Albumin‐Bound Paclitaxel and Nivolumab for PD ‐1 Inhibitor‐Refractory Recurrent or Metastatic Head and Neck Squamous‐Cell Carcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.71533

BibTeX
@article{Adkins2026,
  author = {Adkins, Douglas and Ley, Jessica C and Auberle, Christine and Knapp, Brendan and Zaretsky, Jesse and Liu, Jingxia and Oppelt, Peter},
  title = {Nanoparticle Albumin‐Bound Paclitaxel and Nivolumab for PD ‐1 Inhibitor‐Refractory Recurrent or Metastatic Head and Neck Squamous‐Cell Carcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71533}
}
Kostenlos starten →